Research
If the development of blood vessels in the placenta is impaired, fetal growth retardation may result. Scientists from the German Cancer Research Center (DKFZ) and the Mannheim Medical Faculty of Heidelberg University discovered that the correct development of functioning blood vessels in the mouse placenta is controlled epigenetically: One of the enzymes that modify gene […]
read more
New Member: Welcome in our cluster to Alcedis GmbH
Alcedis is a globally operating, leading full-service CRO with over 30 years of experience in clinical research. As a member of the Huma Group, they combine deep expertise with innovative AI-driven technologies to conduct clinical trials efficiently and accurately – from Phase I to market authorization, medical device projects, and real-world evidence. Their in-house competence […]
read more
curATime is looking for partners!
The curATime cluster is one of 14 pioneering “Clusters4Future” initiatives funded by the German Federal Ministry of Education and Research (BMBF). Its mission is to promote personalized approaches to combat atherothrombosis-related diseases and to establish the Rhine-Main-Palatinate region as an international driver of innovation. For the planned second implementation phase, the cluster is seeking new […]
read more
New approaches against metastatic breast cancer: mini-tumors from circulating cancer cells
Tumor cells circulating in the blood are the “germ cells” of breast cancer metastases. They are very rare and could not be propagated in the culture dish until now, which made research into therapy resistance difficult. A team from the German Cancer Research Center (DKFZ), the Heidelberg Stem Cell Institute HI-STEM* and the NCT Heidelberg** […]
read more
RHEACELL receives EMA approval for allo-APZ2-CVU Phase 3 trial in chronic venous ulcers
Heidelberg, Germany, 19.12.2024 – RHEACELL today received approval from the European Medicines Agency (EMA) for its blinded, multi-centric Phase-3 trial (NCT06489028) evaluating allo-APZ2-CVU in patients with chronic venous ulcers (CVU). The pivotal trial will be conducted at more than 100 sites and is expected to enroll 250 patients, starting enrollment in Europe in Q1 2025. […]
read more
Common cough syrup ingredient shows promise in treating serious lung disease
EMBL scientists discover that an FDA-approved, over-the-counter cough syrup ingredient has potential to treat fibrotic lung disease. Summary A common over-the-counter ingredient in many cough syrups may have a greater purpose for people suffering from lung fibrosis that is related to any number of serious health conditions. Scientists from EMBL Heidelberg were part of a […]
read more
Antibody that Neutralizes Inhibitory Factors Involved in Nerve Regeneration Leads to Enhanced Motor Function after Acute Spinal Cord Injury
Antibodies can improve the rehabilitation of people with acute spinal cord injury. Researchers at 13 clinics in Germany, Switzerland, the Czech Republic and Spain have investigated this with promising results. For the first time, it was possible to identify patient groups that displayed a clinically relevant treatment effect. A follow-up study will start in December […]
read more
Colorectal cancer: role of obesity underestimated to date
Being overweight increases the risk of bowel cancer. The extent of this preventable risk factor has been significantly underestimated to date. Researchers at the German Cancer Research Center (DKFZ) have now reanalyzed a large pool of data and come to the conclusion that obesity is responsible for over 20 percent of bowel cancer cases. More […]
read more
Victoria Stodden to receive Humboldt Research Award
Victoria Stodden, statistician and associate professor at the Daniel J. Epstein Department of Industrial and Systems Engineering at the University of Southern California, has been selected to receive a prestigious Humboldt Research Award. Granted by the Alexander von Humboldt Foundation, the award is bestowed on internationally leading researchers in recognition of outstanding academic achievements. A […]
read more
